Maybe MT resigned before shareholders realised he may mislead them.
Announcement 16 February
This represents a significant milestone for the company as it plans to undertake an adaptive phase 2/3 clinical study in Q2 2024
21 February
Data will be used to support the ODD application and open an IND with US FDA to commence an adaptive 2/3 study in H1 CY 2024
14 March
PAA remains on track to commence pivotal phase 2/3 study for MND/ALS in H1 CY 2024
Then these two statements hidden at the bottom of announcement 16 and 18 April under about PharmAust
PAA anticipates commencing enrolment in the pivotal registration adaptive phase 2/3 clinical study in H2 2024
- Forums
- ASX - By Stock
- PAA
- Ann: Resignation of Dr Michael Thurn & appointment of John Clark
Ann: Resignation of Dr Michael Thurn & appointment of John Clark, page-129
-
- There are more pages in this discussion • 133 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
17.3¢ |
Change
-0.008(4.17%) |
Mkt cap ! $83.90M |
Open | High | Low | Value | Volume |
18.0¢ | 18.0¢ | 17.3¢ | $59.77K | 338.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 376984 | 17.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.5¢ | 25091 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 366984 | 0.170 |
7 | 256513 | 0.165 |
9 | 399304 | 0.160 |
6 | 336734 | 0.155 |
8 | 227993 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 252275 | 4 |
0.185 | 367471 | 6 |
0.190 | 820111 | 8 |
0.195 | 593409 | 10 |
0.200 | 302726 | 11 |
Last trade - 15.42pm 13/09/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online